Immunohistochemical Markers for Prognosis of Cerebral Glioblastomas

McLendon RE, Enterline DS, Tien RD, Thorstad WL, Bruner JM: Tumors of central neuroepithelial origin. In: Bigner DD, McLendon RE, Bruner JM (eds) Russel and Rubinstein's Pathology of Tumors of the Nervous System. vol. 1, 6th edn. Arnold, London, 1998, pp. 387-417 Kleihues P, Cavenee WK: Tumors of the Nervous System. Pathology and Genetics: World Health Organization International Classification ofTumours. IARC press, Lyon, 2000, pp. 72-81 Barker FG II, Chang SM, Larson DA, Sneed P, Wara WM, Wilson CB, Prados MD: Age and radiation respose in glioblastoma multiforme. Neurosurgery 49: 1288-1298, 2001 Barker FG II, Davis RL, Chang SM, Prados MD: Necrosis as prognostic factor in glioblastoma multiforme. Cancer 77: 1161-1166, 1996 Chandler KL, Prados MD, Malec M, Wilson CB: Longterm survival in patients with glioblastoma multiforme. Neurosurgery 32: 716-720, 1993 Cohadon F, Aouad N, Rougier A, Vital C, Rivel J, Dartigues JF: Histologic and non-histologic factors correlated with survival time in supratentorial astrocytic tumors. J Neuro-Oncol 3: 105-111, 1985 Hess KR: Extent of resection as a prognostic variable in the treatment gliomas. J Neuro-Oncol 42: 227-231, 1999 Kreth FW, Berlis A, Spiropouolou V, Faist M, Scheremet R, Rssoner R, Volk B, Ostertag CB: The role of tumor resection in the treatment of glioblastoma multiforme. Cancer 86: 2117-2123, 1999 Lacroix M, AbiSaid D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95: 190-198, 2001 Morita M, Rosenblum MK, Bilsky MH, Fraser RAR, Rosenfeld MR: Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neuro-Oncol 27: 259-266, 1996 Salcman M, Scholtz H, Kaplan RS, Kulik S: Long-term survival in patients with malignant astrocytoma. Neurosurgery 34: 213-220, 1994 Scott JN, Rewcastle NB, Brasher PM, Fulton D, Hagen NA, MacKinnon JA, Sutherland G, Cairncross JG, Forsyth P: Long-term glioblastoma multiforme survivors: a population based study. Can J Neurol Sci 25: 197-201, 1998 Schrieve DC, Alexander E, Black PMcL, Wen PY, Fine HA, Kooy HM, Loeffler JS: Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 90: 72-77, 1999 Vertosick FT, Selker RG: Long-term survival after the diagnosis of malignant glioma. A series of 22 patients surviving more than 4 years after diagnosis. Surg Neurol 38: 359-363, 1992 Al-Sarraj S, Bridges LR: p53 immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg 9: 143-149, 1995 Ang LC, Plewes M, Tan L, Begley H, Agranovich A, Shul D: Proliferating cell nuclear antigen expression in the survival of astrocytoma patients. Can J Neurol Sci 21: 306-310, 1994 Barker FG II, Prados MD, Chang SM, Davis RL, Gutin PH, Lamborn KR, Larson DA, McDermott MW, Snned PK, Wilson CB: Bromdeoxiuridine labeling index in glioblastoma multiforme: Relation to radiation responce, age, and survival. Int J Radiat Oncol Biol Phys 34: 803-808, 1996 Barker FG II, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, Wara WM, Berger MS, Chen P, Israel MA, Alpade KD: EGFR expression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51: 410-418, 2001 Baxendine-Jones J, Campblell I, Ellison D: P53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clin Neuropathol 16: 332-336, 1997 Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Doufor H, Figarella-Branger D: Prognostic significance of Ki-67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol 24: 318-388, 1998 Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, O'Neill BP, Jenkins RB, Alpade KD: Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 8: 180-187, 2002 Chakravarti A, Delaney MA, Noll E, Black PMcL, Loeffler JS, Muzikansky A, Dyson NJ: Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7: 2387-2395, 2001 Chozick BS, Pezullo JC, Epstein MH, Finch PW: Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 35: 831-838, 1994 Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB: Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 86: 121-130, 1997 Deininger MH, Grote E, Wickboldt J, Meyermann R: Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and bcl-2 in glioblastoma multiforme relapses in vivo. J Neuro-Oncol 48: 121-129, 2000 Diedrich U, Lucius J, Baron E, Behnke J, Pabst B, Zoll V: Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol 242: 638-688, 1995 Dorward NL, Hawkins RA, Whittle IR: Epidermal growth factor receptor activity and clinical outcome in glioblastoma and meningioma. Br J Neurosurg 7: 197-199, 1993 Ehrmann JJ, Kolar Z, Vojtesek B, Kala M, Komenda S, Oulto A: Prognostic factors in astrocytomas: relationship of p53, MDM2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival. Neoplasma 44: 299-304, 1997 Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO: Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatr 59: 413-419, 1995 Etienne M-C, Formento J-L, Lebrun-Frenay C, Gioanni G, Chatal M, Paquis P, Bernard C, Courdi A, Bensadoun R-J, Pignol J-P, Francoual M, Grellier P, Frenay M, Milano G: Epidermal growth factor receptor and labelling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 4: 2383-2390, 1998 Galanis E, Buckner J, Kimmel D, Jenkins R, Alderete B, O'Fallon J, Wang CH, Scheithauer BW, James CD: Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol 13: 717-724, 1998 Ganju V, Jenkins RB, O'Fallon JR, Scheithauer BW, Ransom DT, Katzmann JA, Kimmel DW: Prognostic factors in gliomas. A multivariate analysis of clinical pathological, flow cytometric, cytogenetic, and molecular markers. Cancer 74: 920-927, 1994 Grunnet ML, O'Neil A, Gilbert M: Correlation of tumor p53 and PCNA with response and survival of glioblastoma in pateints treated with an ECOG protocol of preirradiation chemotherapy. Clin Neuropathol 19: 230-234, 2000 Hara A, Saegusa M, Mikami T, Okayasu I: Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival. J Clin Pathol 54: 860-865, 2001 Heesters MAAM, Koudstaal J, Go KG, Molenaar WM: Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J Neuro-Oncol 44: 255-266, 1999 Heisiger EM, Hayes RL, Pierz DM, Budzilovich GN: Prognostic relevance of epidermal growth factor receptor (ERF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neuro-Oncol 16: 93-104, 1993 Holden JA, Townsend JJ: DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol 12: 1094-100, 1999 Huhn SL, Mohapatra G, Bollen A, Lamborn K, Prados MD, Feuerstein BG: Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridization: correlation with radiaton treatment. Clin Cancer Res 5: 1435-1443, 1999 Hurtt MR, Moossy J, Donovan-Peluso M, Locker J: Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 51: 84-90, 1992 Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag AM: Prognostic implication of p53 protein, epidermal growth factor receptor and Ki-67 labelling in brain tumor. Br J Cancer 66: 373-385, 1992 Karkavelas G, Mavropoulu S, Fountzilas G, Christoforidou V, Karavelis A, Foroglou G, Papadimitrou C: Correlation of proliferating cell nuclear antigen assessment histologic parameters and age with survival in patients with glioblastoma multiforme. Anticancer Res 15: 531-536, 1995 Kleinschmidt-DeMasters BK, Evans LC, Bobal JB, Lopez-Uribe D, Hopper D, Shroyer AL, Shroyer KR: Quantitative telomerase expression in glioblastomas shows regional variations and down-regulation with therapy but not correlation with patients outcome. Hum Pathol 31: 116-127, 2000 Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E: MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferating markers and epidermal growth factors receptor. Br J Cancer 75: 1269-1278, 1997 Korkolopoulou PA, Konstantinidou AE, Patsorius ES, Christodoulou PN, Thomas-Tsagli EA, Davaris PS: Detection of apoptotic cells in archival tissue from diffuse astrocytomas using a monoclonal antibody to single-stranded DNA. J Pathol 193: 377-382, 2001 Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G, Schlegel U: Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neuro-Oncol 48: 89-94, 2000 Kraus JA, Wenghoefer M, Glesmann N, Mohr C, Beck M, Schmidt MC, Schroder R, Berwieler U, Roggendorf W, Diete S, Deitzmann K, Heuser K, Muller B, Fimmers R, von Deimling A, Schlegel U: TP53 gene mutations, nuclear p53 accumulation, expression Waf/p21, bcl-2 and CD95(APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. J Neuro-Oncol 52: 263-272, 2001 Kyritsis AP, Xu R, Bondy ML, Levin VA, Bruner JM: Correlation of p53 immunoreactivity and sequencing in patients with glioma. Mol Carcinogen 15: 14-18, 1996 Leenstra S, Oskam NT, Bijleveld EH, Bosch DA, Troost D, Hulsebos TJ: Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer 79: 159-165, 1998 Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA: Malignant glioma: genetics and biology of a grave matter. Genes Dev 15: 1311-1333, 2001 Montine TJ, Bruner JM, Vandersteenhoven JJ, Dodge RK, Burger PC: Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms. Diagn Mol Pathol 3: 240-254, 1994 Montine TJ, Vandersteenhoven JJ, Aguzzi A, Boyko OB, Dodge RK, Kerns B, Bruner JM: Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery 34: 674-679, 1994 Newcomb EW, Cohen H, Le SR, Bhalla SK, Bloom J, Hayes RL, Miller DC: Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2, or bcl-2 genes. Brain Pathol 8: 655-667, 1998 Nieder C, Petersen S, Petersen C, Thames HD: The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev 26: 67-73, 2000 Nishizaki T, Kubota H, Harada K, Harada K, Ito H, Suzuki M, Sasaki K: Clinical evidence of distinct subgoups of astrocytic tumors defined by comparative genomic hybridization. Hum Pathol 31: 608-614, 2000 Olson JJ, Barnett D, Yang J, Assietti R, Cotsonins G, James CD: Gene amplification as a prognostic factor in primary brain tumors. Clin Cancer Res 4: 215-222, 1998 Pigott TJD, Lowe JS, Palmer J: Statistical modeling in analysis of prognosis in glioblastoma multiforme: a study of clinical variables and Ki-67 index. Br J Neurosurg 5: 61-66, 1991 Pigott TJD, Robson DK, Palmer J, Ward LM: Expression of epidermal growth factor receptor in human glioblastoma multiforme. Br J Neurosurg 7: 261-265, 1993 Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschläger C, Heidecke V, Burkert W: Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neuro-Oncol 35: 13-28, 1997 Reavey-Cantwell JF, Haroun RI, Zahurak M, Clatterbuck RE, Packer RJ, Mehta R, Fruehauf JP, Brem H: The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neuro-Oncol 55: 195-201, 2001 Rieger L, Weller M, Bornemann A, Schabet M, Dichgans J, Meyermann R: BCL-2 family protein expression in human malignant glioma. A clinical-pathological correlative study. J Neurol Sci 155: 68-75, 1998 Rhodes RH: Biological evaluation of biopsies from adult cerebral astrocytomas: cell-growth/cell-suicide ratios and their relationship to patient survival. J Neuropathol Exp Neurol 57: 746-757, 1998 Rodriguez-Pereira C, Suarez-Peneranda JM, Barros F, Sobrido MJ, Vazquez-Salvado M, Fortez J: Analysis of 2 antiapoptotic factors in gliomas. bcl-2 overexpression and p53 mutation. Arch Pathol Lab Med 125: 218-223, 2001 Sallinen PK, Haapasalo HK, Visakorpi T, Helin PT, Rantala IS: Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA and S-phase fraction using archival paraffin-embedded samples. J Pathol 174: 275-282, 1994 Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WKA, Steck PA: Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59: 1820-1824, 1999 Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes M, Kiessling M: Amplification of epidermalgrowth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 56: 72-77, 1994 Schober R, Bilzer T, Waha A, Reifenberger J, Wechsler W, von Demling A, Wiestler OD, Westphal M, Kemshead JT, Vega F, Delattre JY, Stasiecki-Steinfeld P: The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression and patient survival data in a therapeutic trial. Clin Neuropathol 14: 169-174, 1995 Simmons ML, Lamborn KL, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG II, Alpade K: Analysis of complex relationships between age, p53, EGFR, and survival in glioblastoma patients. Cancer Res 61: 1122-1128, 2001 Smith JS, Jenkins RB: Genetic alteration in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci 5: D213-D231, 2000 Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB: PTEN mutation, EGFR amplification and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93: 1246-1256, 2001 SoiniY, Nyemela A, Kamel D, Herva R, Bloigu R, Pekki P: p53 immunohistichemcial positivity as a prognostic marker in intracranial tumours. APMIS 102: 786-792, 1993 Stemmer Rachamimov AO, Louis DN: Histopathologic and immunohistochemical prognostic factors in malignant gliomas. Curr Opin Oncol 9: 230-234, 1997 Tamiya T, Mizumatsu S, Ono Y, Abe T, Matsumoto K, Furuta T, Ohmoto T: High cyclin E/lowp27kip1 expression is associated with poor prognosis in astrocytomas. Acta Neuropathol (Berl) 101: 334-340, 2001 Taniguchi K, Wakabayashi T, Yoshida T: Immunohistochemical staining of DNA topoisomerase II a in human gliomas. J Neurosurg 91: 477-482, 1999 Theunissen PHMH, Blaauw J: Proliferating cell nuclear antigen immunostaining and survival in cerebral astrocytomas. Histopathology 23: 75-79, 1993 Torp SH, Helseth E, Dalen A, Unsgaard G: Relationship between Ki-67 labelling index, amplification of epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochir (Wien) 117: 182-186, 1992 Vaquero J, Zurita M, Morales C, Oya S, Coca S: Prognostic significance of endothelial surface score and MIB-1 labeling index in glioblastoma. J Neuro-Oncol 46: 11-16, 2000 Waha A, Baumann A, Wolf HK, Fimmers R, Neumann J, Kindermann D, Astrahantseff K, Blumke A, von Deimling A, Schlegel U: Lack of prognostic relevance of alterations in epidermal growth factor receptortransforming growth factor a pathway in human astrocytic gliomas. J Neurosurg 85: 634-641, 1996 Zhu A, Shaeffer J, Leslie S, Kolm P, El-Mahdi AM: Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive radiation. Int J Radiat Oncol Biol Phys 34: 809-815, 1996 Golanov A, Korshunov A: Immunohistochemical study of proliferative activity and p53 oncoprotein expression in different cytological phenotypes of the cerebral glioblastomas. Clin Neurol Neurosurg 99(Suppl 1): 30, 1997 Burger PC, Vollmer RT: Histologic factors of prognostic significance in the glioblastoma multiforme. Cancer 46: 1179-1186, 1980 Burger PC, Vogel S, Green SB, Strike TA: Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56: 1106-1111, 1985 Burger PC, Green SB: Patient age, histological features and length of survival in patients with glioblastoma multiforme. Cancer 59: 1617-1625, 1997 Giangaspero F, Burger PC: Correlations between cytologic composition and biologic behavior in the glioblastoma multiforme. A postmortem study of 50 cases. Cancer 52: 2320-2333, 1983 Kraus JA, Wenghoefer M, Schmidt MC, von Deimling A, Berwieler U, Roggendorf W, Diete S, Deitzmann K, Heuser K, Muller B, Heuser K, Reifenberger G, Schlegel U: Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. J Neurol 247: 455-460, 2000 Haas-Kogan DA, Yount G, Haas M, Levi D, Kogan SS, Hsu L: p53-dependent G 1 arrest and p53 independent apoptosis influence the radiobiologic response of gliobalstoma. Int J Radiat Oncol Biol Phys 36: 95-103, 1996 Kraus A, Gross MW, Knuechel R, Munkel K, Neff F, Schlegel J: Aberrant p21 regulation in radioresistant primary glioblastoma multiforme cells bearing wild-type p53. J Neurosurg 93: 863-872, 2000 Tribius S, Pidel A, Casper D: ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. J Radiat Oncol Biol Phys 50: 511-523, 2001 Shu HKG, Kim MM, Chen P: The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21-BAX expression. Proc Natl Acad Sci 95: 399-403, 1998 Haas-Kogan DA, Kogan SS, Yount J, Hsu H, Haas M, Deen DF, Israel MA: p53-function influences the effect of fractionated radiotherapy on gliobalstoma tumors. Int J Radiat Oncol Biol Phys 43: 399-403, 1999 Tada M, Matsumoto R, Igga RD, Onimaru R, Shirato H, Sawamura Y, Shinohe Y: Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutation. Cancer Res 40: 57-63, 1998 Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180-185, 1997 Matsumoto R, Tada M, Nozaki M, Zhang CL, Sawamura Y, Abe H: Short alternative splice transcripts of the mdm2 oncogene correlate to maligancy in human astrocytic neoplasms. Cancer Res 58: 609-613, 1998 Ellison DW, Steart PV, Gatter KC, Weller RO: Apoptosis in cerebral astrocytic tumors and its relationship to expression of BCL-2 and p53 proteins. Neuropathol Appl Neurobiol 21: 352-361, 1995 Krajewski S, Krajewska M, Ehramann J, Sikorska M, Lach B, Chatten J: Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1 and Bax in tumors of central and peripheral nervous system. Am J Pathol 150: 805-814, 1997 Krishna M, Smith TW, Recht LD: Expression of bcl-2 in reactive and neoplastic astrocytes: lack of correlation with presence of degree of malignancy. J Neurosurg 83: 1017-1022, 1995 Nakasu S, Nakasu Y, Nioka H, Nakajima M, Handa J: Bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol (Berl) 88: 520-526, 1994 Schiffer D, Cavalla P, Migheli A, Giordana MT, Chiado-Piat L: Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical study. J Neuro-Oncol 27: 101-109, 1996 Weiner H: The role of growth factor receptors in central nervous system development and neoplasia. Neurosurgery 37: 179-194, 1995 Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP: Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastoma with EGFR gene amplification. Oncogene 9: 2313-2320, 1994 Luwor RB, Johns TG, Murone C, Huang H-JS, Cawenee WK, Ritter G, Old LJ, Burgess A, Scott AM: Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61: 5355-5361, 2001 Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ: Monoclonal antibodies against EGFr vIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55: 3140-3148, 1995 Nagane M, Coufal F, Lin H, Bhogler O, Cavenee WK, Huang HJ: A common mutant epidermal growth factor receptor enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56: 5079-5086, 1996 Nagane M, Lin H, Cavenee WK, Huang HJ: Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett 162: 17-21, 2001 Feun LJ, Savaraj N, Landy HJ: Drug resistance in brain tumors. J Neuro-Oncol 20: 165-176, 1994 Beiswanger CM, Diegmann MH, Novak RF, Philbert MA, Garessle TL, Reuhl KR, Lowndes HE: Developmental changes in the cellular distribution of glutathione and glutathione S-transferases in murine nervous system. Neurotoxicology 16: 425-440, 1995 Philbert MA, Bieswanger CM, Manson MM, Green 2JA, Novak RF, Primiano T, Reuhl KR, Lowndes HE: Glutathione S-transferases and gamma-glutamyl transpeptidase in the rat nervous systen: a basis for differential susceptibility to neurotoxicants. Neurotoxicology 16: 339-342, 1995 Ali-Osman F, Brunner JM, Kultuk TM, Hess K: Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res 3: 2253-2261, 1997 Bossanyi von P, Diete S, Dietzmann K, Warich Kirches M, Kirches E: Immuno-histochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol (Berl) 94: 605-611, 1997 Strange RC, Lear JT, Fryer AA: Polymorphism in glutathione S-transpherase loci as a risk factor for common cancers. Arch Toxicol Suppl 20: 419-428, 1998 Besson A, Yong VW: Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas. J Neuro-Oncol 51: 245-264, 2001 Fults D, Petronio J, Noblett BD, Pedone CA: Chromosome 11p15 deletions in human malignant astrocytomas and primitive neuroectodermal tumors. Genomics 14: 799-801, 1992 Blumenstock M, Prosenc N, Patt S, Pfanne K, Drum F, Cervos-Navarro J: In contrast to EGFr gene overexpression, H-ras gene expression decreases in human gliomas. Anticancer Res 11: 1353-1357, 1991 Feldkamp MM, Lala P, Lau N, Roncari L, Guha A: Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma specimens. Neurosurgery 45: 1442-1453, 1999 Gomori E, Doszi T, Pajor L, Matolcsy A: Sporadic p53 mutations and absence of ras mutations in glioblastomas. Acta Neurochir (Wien) 141: 593-599, 1999 Sonoda Y, Ozawa T, Alpade KD, Deen DF, Berger MS, Pieper RO: Akt pathways activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 61: 6674-6678, 2001 Sonoda Y, Ozawa T, Hirose Y, Alpade KD, McMahon M, Berger MS, Pieper RO: Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in development of human anaplastic astrocytoma. Cancer Res 61: 4956-4960, 2001 Salgaller M, Pearl D, Stephens R: In situ hybridization with single stranded RNA probes to demonstrate infrequently elevated gli mRNA and no increased ras mRNA levels in meningiomas and astrocytomas. Cancer Lett 57: 243-253, 1991 Bian XW, Shi JQ, Liu FX: Pathologic significance of proliferative activity and oncoprotein expression in astrocytic tumors. Anal Quant Cytol Histol 22: 429-437, 2000 Gulbins E, Bissonnete R, Mahboubi A: Fas-induced apoptosis is mediated via a ceramide initiated RAS signaling pathway. Immunity 2: 341-351, 1995 Croce CM: How can we prevent cancer ? Proc Natl Acad Sci USA 98: 10986-10988, 2001 Langlois NE, Eremin O, Heys SD: Apoptosis and prognosis in cancer: rationale and relevance. J R Coll Surg Edinb 45: 211-219, 2000 Tamm I, Schriever F, Droken B: Apoptosis: implication of basic research in clinical oncology. Lancet Oncol 2: 33-42, 2001 Savitz SI, Rosenbaum DM: Apoptosis in neurological desease. Neurosurgery 42: 555-574, 1998 Carrol RS, Zhang J, Chauncey BW: Apoptosis in atrocytic neoplasms. Acta Neurochir (Wien) 139: 845-850, 1997 Kordek R, Hironoshi N, Liberski PP, Yanagihara R, Gajdushek DC: Apoptosis in glial tumors as determined by in situ nonradioactive labeling of DNA breaks. Acta Neuropathol (Berl) 91: 112-116, 1996 Kokunai T, Sawa H, Tamaki N: Localization of apoptotic cells in situ of brain tumors. Brain Tumor Pathol 12: 15-21, 1995 Migheli A, Cavalla P, Marino S, Schiffer D: A study of apoptosis in normal and pathological nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol 53: 606-616, 1994 Mizoguchi M, Inamura T, Shono T, Ikezaki K, Inoha S, Ohgama S, Fukui M: A comparative study of apoptosis and proliferation in germinoma and glioblastoma. Neuro-Oncology 2: 96-102, 2000 Patsouris E, Davaki P, Kapranos N, Davaris P, Papageorgiou K: A study of apoptosis in brain tumors by in situ end-labelling method. Clin Neuropathol 15: 337-341, 1996 Yew DT, Wang HH, Zheng DR: Apoptosis in astrocytomas with different grades of malignancy. Acta Neurochir (Wien) 140: 341-347, 1998 Imitola J, Nikas DS, Black PMcL: Apoptosis in tumors of the central nervous system. Crit Rev Neurosurg 7: 391-399, 1997 Nakatsu S, Kondo S, Yin D, Peterson JV, Kaakaji R, Morimura T: Induction of apoptosis in multi-drug resistance (MDR) human glioblastoma cells by SN-38, a metabolite of the campothecin deprivate CTP 11. Cancer Chemother Pharmacol 71: 417-423, 1997 Scherer HJ: The forms of growth in gliomas and their practical significance. Brain 63: 1-35, 1940 Kleihues P, Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncology 1: 44-51, 1999 von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19-26, 1993 Burger PC, Pearl DK, Aldape K, Yates AJ, Scheithauer BW, Passe SM, Jenkins RB, James CD: Small cell architecture-a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 60: 1099-1104, 2001 Tachibana O, Lampe J, Kleihues P, Ohgaki H: Preferntial expression of Fas/APO (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathol 92: 431-434, 1996 Tohma Y, Gratas C, Van Meir EG, Disbaillets I, Tenan M, Tachibana O, Kleihues P, Ohgaki H: Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol 57: 239-245, 1998 Louis DN, Holland EC, Cairncross JG: Glioma classification: a molecular reappraisal. Am J Pathol 159: 779-786, 2001